

# THERAPEUTIC APPROACHES TO PRESERVE ISLET MASS IN TYPE 2 DIABETES

---

Laurie L. Baggio and Daniel J. Drucker

*Department of Medicine, Toronto General Hospital, Banting and Best Diabetes Center, University of Toronto, Toronto, Ontario, Canada M5S 2S2; email: d.drucker@utoronto.ca*

**Key Words**  $\beta$ -cell mass, apoptosis, neogenesis, proliferation

■ **Abstract** Type 2 diabetes is characterized by hyperglycemia resulting from insulin resistance in the setting of inadequate  $\beta$ -cell compensation. Currently available therapeutic agents lower blood glucose through multiple mechanisms but do not directly reverse the decline in  $\beta$ -cell mass. Glucagon-like peptide-1 (GLP-1) receptor agonists, exemplified by Exenatide (exendin-4), not only acutely lower blood glucose but also engage signaling pathways in the islet  $\beta$ -cell that lead to stimulation of  $\beta$ -cell replication and inhibition of  $\beta$ -cell apoptosis. Similarly, glucose-dependent insulinotropic polypeptide (GIP) receptor activation stimulates insulin secretion, enhances  $\beta$ -cell proliferation, and reduces apoptosis. Moreover, potentiation of the endogenous postprandial levels of GLP-1 and GIP via inhibition of dipeptidyl peptidase-IV (DPP-IV) also expands  $\beta$ -cell mass via related mechanisms. The thiazolidinediones (TZDs) enhance insulin sensitivity, reduce blood glucose levels, and also preserve  $\beta$ -cell mass, although it remains unclear whether TZDs affect  $\beta$ -cell mass via direct mechanisms. Complementary approaches to regeneration of  $\beta$ -cell mass involve combinations of factors, exemplified by epidermal growth factor and gastrin, which promote islet neogenesis and ameliorate diabetes in rodent studies. Considerable preclinical data support the concept that one or more of these therapeutic approaches, alone or in combination, may potentially reverse the decline in  $\beta$ -cell mass that is characteristic of the natural history of type 2 diabetes.

## INTRODUCTION

Type 2 diabetes, also known as non-insulin-dependent diabetes mellitus, accounts for >90% of diabetes worldwide. It is characterized by impaired insulin action (insulin resistance) in peripheral tissues, principally muscle, adipose tissue, and liver, in association with a deficient  $\beta$ -cell insulin-secretory response to glucose. The pathogenesis of type 2 diabetes involves a combination of genetic and environmental/lifestyle factors and is frequently associated with obesity (1). Patients with type 2 diabetes have an increased risk of developing both microvascular and macrovascular disease and associated complications, including nephropathy, neuropathy, retinopathy, and cardiovascular disease. The global incidence of type 2

diabetes has been increasing steadily in the past several years, partly because of an increased prevalence of obesity, a more sedentary lifestyle, and a rise in the average age of the general population (2). There has also been a significant rise in the incidence of obesity and type 2 diabetes among children and adolescents (3). Thus, type 2 diabetes is now a major public health problem that places a severe economic burden on health care systems.

Traditional medications for type 2 diabetes, including insulin, sulfonylureas, glitinides, acarbose, metformin, and thiazolidinediones, lower blood glucose through diverse mechanisms of action. Studies such as the United Kingdom Prospective Diabetes Study (UKPDS) clearly illustrate that better glycemic control achieved with some of these drugs can significantly reduce the development of diabetes-associated secondary complications (4). However, many of the oral hypoglycemic agents lose their efficacy over time, resulting in progressive deterioration in  $\beta$ -cell function and loss of glycemic control.

The reasons why current antidiabetic agents become less effective over time are not well understood, but they appear to include progressive loss of  $\beta$ -cell mass. Autopsy studies demonstrate that  $\beta$ -cell mass is decreased in type 2 diabetes despite a normal capacity for  $\beta$ -cell replication and neogenesis (5–8).  $\beta$ -cell mass is governed by a combination of factors: (a) replication of existing  $\beta$ -cells, (b) differentiation of new  $\beta$ -cells from ductal and extraislet precursor cells (neogenesis), and (c)  $\beta$ -cell apoptosis (9–11). Reduced  $\beta$ -cell mass has been observed in both obese and lean type 2 diabetic humans (5) and in diabetic rodent models of genetic and experimental diabetes (12). Commonly observed in both human and rodent studies of type 2 diabetes is an increase in  $\beta$ -cell apoptosis (5, 13, 14); the mechanisms responsible include chronic hyperglycemia, dyslipidemia, endoplasmic reticulum and oxidative stress, islet amyloid deposition, and actions of inflammatory cytokines (reviewed in 15, 16).

Medications currently used to treat type 2 diabetes cannot prevent  $\beta$ -cell death or re-establish  $\beta$ -cell mass. Moreover, short-term studies demonstrate that sulfonylureas can induce apoptosis in rodent  $\beta$ -cells (17) or cultured human islets (18). Thus, sulfonylurea therapy could theoretically exacerbate  $\beta$ -cell loss in subjects with type 2 diabetes. Consequently, there has been intense interest in the development of therapeutic agents that preserve or restore functional  $\beta$ -cell mass. Several agents with the potential to inhibit  $\beta$ -cell apoptosis and/or increase  $\beta$ -cell mass have been identified in preclinical studies (Figure 1, Table 1).

## GLP-1 RECEPTOR AGONISTS

Glucagon-like peptide-1 (GLP-1), a potent glucoregulatory hormone, is produced in enteroendocrine L-cells by tissue-specific post-translational processing of proglucagon and is released into the circulation in response to nutrient ingestion (19). GLP-1 regulates glucose homeostasis by stimulating glucose-dependent insulin secretion and biosynthesis, and by suppressing glucagon secretion, gastric emptying, and appetite (20). GLP-1 may also enhance insulin-independent

**TABLE 1** Agents that increase or preserve  $\beta$ -cell mass

<b>Stimulators of <math>\beta</math>-cell proliferation and/or neogenesis</b>	<b>Inhibitors of <math>\beta</math>-cell death</b>
GLP-1	GLP-1
GIP	GIP
DPP-IV inhibitors	DPP-IV inhibitors
Epidermal growth factor/gastrin	Growth hormone
TZDs	Hepatocyte growth factor
Growth hormone	Insulin-like growth factors
Hepatocyte growth factor	Parathyroid hormone-related peptide
Human placental lactogen	
INGAP	
Insulin-like growth factors	
Parathyroid hormone-related peptide	
Prolactin	
Keratinocyte growth factor	
Betacellulin	

Abbreviations: GLP-1, glucagon-like peptide-1; GIP, glucose-dependent insulinotropic polypeptide; DPP-IV, dipeptidyl-peptidase-IV; TZDs, thiazolidinediones; INGAP, islet neogenesis-associated protein.

glucose disposal in peripheral tissues (21–23). Activation of GLP-1 receptor (GLP-1R) signaling also increases  $\beta$ -cell mass by stimulating  $\beta$ -cell proliferation and neogenesis and inhibiting  $\beta$ -cell apoptosis (24, 57).

The actions of GLP-1 have generated a great deal of interest in using this peptide for the treatment of type 2 diabetes (23). However, the therapeutic potential of native GLP-1 is limited by its very short plasma half-life ( $\sim 90$  s), which is due to rapid inactivation by the ubiquitous protease dipeptidyl peptidase-IV (DPP-IV) and renal clearance (25–29). Consequently, long-acting, DPP-IV-resistant GLP-1R agonists have been developed for clinical use, including exendin-4 (Exenatide) and the fatty-acyl-derivatized GLP-1 analogue liraglutide. These agents are GLP-1 mimetics that bind the GLP-1R with similar affinity and elicit biological actions identical to those of native GLP-1, but they resist DPP-IV-mediated inactivation and renal clearance and thus can sustain protracted activation of the GLP-1R (30, 31).

The ability of GLP-1R agonists to expand  $\beta$ -cell mass via stimulation of  $\beta$ -cell growth and prevention of  $\beta$ -cell death has been demonstrated in studies using islet and  $\beta$ -cell primary cultures or cell lines, as well as in experiments using normal and diabetic rodents. GLP-1 activates the expression of immediate early genes in rat insulinoma-derived, insulin-secreting (INS-1) cells (32, 33), and treatment of pancreatic exocrine cells or rat pancreatic ductal cell lines with GLP-1 or exendin-4 promotes their conversion into islet-like cells that produce and secrete insulin in a glucose-dependent manner (34, 35). GLP-1, exendin-4 and liraglutide (36)

inhibit apoptosis in primary rodent islets, purified  $\beta$ -cells, and islet cell lines that have been exposed to cytotoxic agents (37–40). GLP-1R agonists improve glucose tolerance, enhance  $\beta$ -cell proliferation and neogenesis, and inhibit  $\beta$ -cell apoptosis in rodent models of diabetes, leading to increased  $\beta$ -cell mass (38, 41–48). Moreover, administration of exendin-4 during the prediabetic neonatal period prevents adult-onset diabetes in rats following experimentally induced intrauterine growth retardation (49). Similarly, exendin-4 increases  $\beta$ -cell mass and delays the onset of diabetes in db/db mice and Goto-Kakizaki rats (48, 50). Of direct relevance to the potential use of these agents for the treatment of type 2 diabetes in humans, exendin-4 promotes the differentiation of human fetal islet and pancreatic ductal cells into cells that produce and secrete insulin in a glucose-dependent manner (35, 51, 52), and GLP-1 preserves morphology, improves glucose-stimulated insulin secretion, and inhibits apoptosis in freshly isolated human islets (39, 53).

The physiological importance of the known GLP-1R for the proliferative, neogenic, and antiapoptotic actions of GLP-1 is exemplified by studies employing the GLP-1R antagonist exendin (9–39), or experiments in mice with targeted genetic inactivation of the GLP-1R gene (GLP-1R<sup>-/-</sup>). Exendin (9–39) blocks GLP-1R agonist-mediated differentiation of human pancreatic ductal cells (52) and inhibits the antiapoptotic effects of GLP-1 in mouse insulinoma-derived (MIN6)  $\beta$ -cells (37). Although treatment of wild-type mice with exendin (9–39) did not impair the islet regenerative response to partial pancreatectomy, GLP-1R<sup>-/-</sup> mice exhibited defective regeneration of  $\beta$ -cell mass and deterioration of glucose tolerance in the same experimental paradigm (54). Furthermore, GLP-1R<sup>-/-</sup> mice display increased susceptibility to islet apoptosis and worsening hyperglycemia following administration of the  $\beta$ -cell toxin streptozotocin (38). Hence it appears that endogenous GLP-1R signaling is essential for  $\beta$ -cell cytoprotection in vivo.

How does GLP-1R activation lead to increased  $\beta$ -cell mass? The molecular mechanisms are diverse and involve multiple signal transduction pathways downstream of the GLP-1R (Figure 2) (24, 55). The GLP-1R-dependent signaling pathways responsible for the proliferative, neogenic, and antiapoptotic actions of GLP-1R agonists have been examined using human or rodent primary islets, rodent  $\beta$ -cell lines, and diabetic mice (reviewed in 55–57). A common element in all of these GLP-1R-dependent pathways is activation of pancreatic and duodenal homeobox factor-1 (PDX-1), a transcription factor essential for pancreas development and  $\beta$ -cell function (34, 35, 43, 44, 51, 52, 58). The proliferative effects of GLP-1R agonists may also be mediated by transactivation of the epidermal growth factor receptor (EGFR), which leads to increases in phosphatidylinositol-3 kinase (PI-3K) and activation of protein kinase C (PKC)  $\zeta$  (59) and/or Akt-protein kinase B (PKB) (60). The precise mechanisms involved in GLP-1-dependent  $\beta$ -cell differentiation/neogenesis are poorly defined but may involve activation of PKC and mitogen-activated protein kinase (MAPK) (34). More recent studies have demonstrated that exendin-4 mediates  $\beta$ -cell regeneration in streptozotocin-treated mice by mechanisms that involve upregulating insulin receptor substrate-2 (IRS-2) expression and promoting nuclear exclusion of the transcription factor

Foxo 1 [a key negative regulator of  $\beta$ -cell growth (61)], thereby increasing PDX-1 expression (58).

The antiapoptotic effects of GLP-1R agonists are associated with reductions in the levels of proapoptotic proteins such as active caspase 3 and poly-ADP-ribose polymerase (PARP) cleavage, as well as upregulation of prosurvival factors including Bcl-2, Bcl-xL, and inhibitor of apoptosis protein-2 (IAP-2) (37, 39, 47, 48, 62). GLP-1R-dependent inhibition of  $\beta$ -cell apoptosis is coupled to (a) activation of cAMP/protein kinase A (PKA) with subsequent phosphorylation and activation of cAMP response element binding protein (CREB), leading to activation of IRS-2 and induction of the Akt-PKB growth and survival pathway (48, 63), and (b) activation of Akt-PKB and enhancement of the DNA binding activity of its downstream target, nuclear factor- $\kappa$ B (NF $\kappa$ B), a transcription factor that plays an important role in the regulation of apoptosis (39).

Clinical studies have demonstrated that GLP-1R agonists can enhance glucose-stimulated insulin secretion, reduce fasting and postprandial blood glucose levels, promote satiety and weight loss, and lower hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) and plasma levels of free fatty acids (23, 64–68). Hence, GLP-1R agonists may preserve  $\beta$ -cell mass via both direct and indirect actions. Direct activation of GLP-1Rs on pancreatic  $\beta$ -cells or islet precursors can stimulate signal transduction pathways that modify  $\beta$ -cell proliferation, neogenesis, and apoptosis. Chronic treatment with GLP-1R agonists improves metabolic control in type 2 diabetic patients (69–71) by reducing hyperglycemia and levels of circulating free fatty acids, thereby indirectly protecting  $\beta$ -cells from the deleterious effects of high glucose and lipid levels.

## GIP

Glucose-dependent insulintropic polypeptide (GIP) is a 42-amino-acid hormone released from intestinal K-cells in response to nutrient ingestion. Like GLP-1, it enhances glucose-stimulated insulin secretion and biosynthesis and promotes  $\beta$ -cell proliferation and survival (72). Most studies examining the proliferative and antiapoptotic actions of GIP have employed either heterologous cells transfected with the GIP receptor (GIPR) or rodent  $\beta$ -cell lines. Important effectors of GIP action include cAMP/PKA, PKA/CREB, MAPK, and PI-3K activation of Akt-PKB (73–76). In comparison, relatively little is known about the signal transduction pathways that modify GIPR-dependent  $\beta$ -cell growth and survival in vivo. Systemic administration of GIP significantly reduced islet cell apoptosis in diabetic rats (77). GIP inhibits  $\beta$ -cell apoptosis by activation of PI-3K/Akt-PKB and subsequent phosphorylation of Foxo1. Phosphorylated Foxo1 is exported from the nucleus and sequesters within the cytoplasm following GIPR activation, resulting in reduced expression of the proapoptotic *bax* gene and upregulation of the antiapoptotic *bcl-2* gene (77).

Although GIP appears to be a promising candidate for the treatment of type 2 diabetes, humans with type 2 diabetes are relatively resistant to the insulintropic

effects of exogenous GIP administration (78, 79). Preclinical data suggest that continuous exposure to GIP and/or hyperglycemia promotes downregulation of GIPR expression *in vivo* (80). However, improvement of glycemic control following four weeks of treatment with a sulfonylurea enhanced the acute insulinotropic response to GIP in subjects with type 2 diabetes (81). Thus, the clinical potential of GIP or long-acting GIPR agonists requires further study.

## DPP-IV INHIBITORS

Dipeptidyl peptidase-IV (DPP-IV) is a ubiquitously expressed proteolytic enzyme that specifically cleaves dipeptides from the amino terminus of oligopeptides or proteins that contain an alanine or proline residue in position two (26). DPP-IV is a critical determinant of GLP-1 and GIP inactivation *in vivo* (25). Both GLP-1 and GIP have an alanine residue in the penultimate position and are rapidly inactivated by DPP-IV, so that, in humans, the plasma half-life for GLP-1 is  $\sim 2$  min and that of GIP is  $\sim 5$  min (82, 83). Because of the clinical potential of GLP-1 and GIP for the treatment of type 2 diabetes, DPP-IV inhibitors have been developed to prevent proteolytic inactivation of endogenous GLP-1 and GIP. Several orally active DPP-IV inhibitors are currently being evaluated for the treatment of type 2 diabetes (84).

Numerous preclinical studies with both normal and diabetic animals clearly demonstrate that pharmacological inhibition of DPP-IV activity increases endogenous plasma levels of intact, biologically active GLP-1 and GIP, enhances insulin secretion, reduces peripheral insulin resistance, and improves glucose tolerance (85–93). Moreover, mice with a targeted disruption of the DPP-IV gene exhibit improved glucose tolerance in association with increased levels of plasma insulin and bioactive GIP and GLP-1 (94). Human studies are fewer, but they have established that treatment with DPP-IV inhibitors improves  $\beta$ -cell function, reduces fasting and postprandial blood glucose levels, and decreases HbA<sub>1c</sub> values in subjects with type 2 diabetes (95–97).

In addition to GLP-1 and GIP, regulatory peptides, neuropeptides, and chemokines are potential substrates for the proteolytic actions of DPP-IV (98). Pituitary adenylate cyclase-activating peptide (PACAP) is a neuropeptide that stimulates glucose-dependent insulin secretion and can reduce blood glucose levels in diabetic animals (99). Transgenic overexpression of PACAP in pancreatic  $\beta$ -cells is associated with increased  $\beta$ -cell proliferation in mice following streptozotocin administration (100). This suggests that PACAP may also play a role in enhancing  $\beta$ -cell mass. Furthermore, inhibition of DPP-IV activity in mice potentiates the insulin-secretory response to exogenous PACAP (101). However, DPP-IV inhibitors do not lower blood glucose levels following acute administration in mice that lack receptors for both GLP-1 and GIP, suggesting that DPP-IV inhibitors mediate their glucose-lowering actions primarily through GLP-1- and GIP-dependent actions (102).

There is active interest in determining whether treatment with DPP-IV inhibitors will increase  $\beta$ -cell mass. Twice-daily administration of the DPP-IV inhibitor

P32/98 for seven days increased levels of bioactive GLP-1, improved glucose tolerance, and enhanced pancreatic insulin content while stimulating both islet neogenesis and  $\beta$ -cell survival in diabetic rats (103). Treatment of mice for eight weeks with the DPP-IV inhibitor NVP DPP728 improved  $\beta$ -cell function and reduced islet size relative to high-fat-fed control mice (104). Conversely, mice deficient in DPP-IV are resistant to streptozotocin-induced reductions in  $\beta$ -cell mass (105). Taken together, the data imply a role for long-term DPP-IV inhibition in the regulation of  $\beta$ -cell mass in type 2 diabetes.

## GASTRIN AND EGF

Gastrin is a peptide hormone that stimulates gastric acid secretion and neuroendocrine cell proliferation in the gastric mucosa of adult animals (106). During fetal development, gastrin and its receptors are expressed primarily in the developing pancreas at a time when islet precursor cells are undergoing active proliferation and differentiation to form new islets (107, 108), which suggests a potential role for gastrin in islet neogenesis. Studies in the regenerating pancreas of duct-ligated rats revealed that gastrin stimulates  $\beta$ -cell neogenesis and expansion of  $\beta$ -cell mass from transdifferentiated, but not normal, exocrine pancreas tissue (109). Analyses of epidermal growth factor (EGF) actions demonstrate that it may activate the proliferation of ductal islet precursor cells (110, 111). Early evidence that a combination of gastrin and EGF could stimulate islet neogenesis and increase  $\beta$ -cell mass emerged from studies using single- or double-transgenic mice that express transforming growth factor- $\alpha$  (TGF- $\alpha$ ), an EGFR ligand, and/or gastrin under the control of the insulin promoter (112). In gastrin transgenic mice, pancreatic ductal tissue and islet mass are normal, whereas in TGF- $\alpha$  transgenic mice, the number of insulin-expressing pancreatic ductal cells is increased but islet mass is normal. However, TGF- $\alpha$ /gastrin double-transgenic mice exhibit significantly increased  $\beta$ -cell mass. These observations formed the basis for the hypothesis that gastrin and EGFR ligands act synergistically to stimulate islet growth, with EGFR ligands initiating a program of islet differentiation that is completed by gastrin (112).

The therapeutic potential of combined gastrin and EGF was illustrated by studies in which gastrin/EGF reduced hyperglycemia, induced islet regeneration, and increased  $\beta$ -cell mass in rodent models of genetic or chemically induced insulin-dependent (type 1) diabetes, whereas gastrin or EGF alone were not effective (113, 114, 114a). More recent studies have shown that gastrin/EGF can also increase  $\beta$ -cell mass in islet preparations derived from adult human pancreatic tissue (115). Gastrin/EGF increased the number of  $\beta$ -cells in cultured human islets, and this effect was sustained for up to four weeks after removal of gastrin/EGF from the culture medium. Pancreatic ductal cells are consistently present in human islet preparations (116), and the increased  $\beta$ -cell number was attributed to the activation of  $\beta$ -cell neogenesis mediated by EGF stimulation of ductal cell proliferation and gastrin-dependent increases in ductal cell PDX-1 expression and differentiation (115). Gastrin/EGF also increased functional  $\beta$ -cell mass following transplantation

of human islets into diabetic mice (115). The ability of gastrin/EGF therapy to induce  $\beta$ -cell neogenesis from pancreatic ductal cells has potential implications for new approaches to the treatment of type 1 and type 2 diabetes and is currently being evaluated in early-stage clinical trials. Whether cholecystokinin (CCK), acting presumably via the CCK-B receptor, will exert similar trophic effects on pancreatic islet growth is also under active investigation (117).

## THIAZOLIDINEDIONES

The thiazolidinediones (TZDs) are ligands for peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ), a nuclear hormone receptor that functions as a transcription factor and regulates the expression of genes that modify cellular differentiation and glucose and lipid metabolism (118). TZDs enhance insulin sensitivity in peripheral tissues, lower blood glucose, exert anti-inflammatory effects, and improve metabolic control in type 2 diabetic individuals (119, 120).

TZDs have also been shown to enhance  $\beta$ -cell function in diabetic humans and rodents and to preserve  $\beta$ -cell mass and delay the onset of hyperglycemia in rodent models of type 2 diabetes (121–124). The TZD rosiglitazone prevented the development of diabetes in Zucker diabetic fatty rats when administered during the prediabetic period (122). Rosiglitazone also inhibited the well-characterized progressive loss of  $\beta$ -cell mass in these animals by maintaining  $\beta$ -cell proliferation, thereby preventing increases in overall net  $\beta$ -cell death (122). In human islets, the TZD pioglitazone inhibited hyperglycemia- or cytokine-induced apoptosis by blocking activation of the NF $\kappa$ B pathway, a major proapoptotic signal transduction pathway in human  $\beta$ -cells (125). Thus, in addition to improving peripheral insulin sensitivity, TZDs can also preserve  $\beta$ -cell mass in the setting of type 2 diabetes or  $\beta$ -cell injury. However, whether TZDs mediate these effects directly, via activation of pancreatic  $\beta$ -cell PPAR $\gamma$  receptors, or indirectly, by normalizing blood glucose levels and improving metabolic parameters, is not known. Moreover, whether TZD-mediated enhancement of  $\beta$ -cell function and preservation of  $\beta$ -cell mass are related to reduced  $\beta$ -cell secretory demand as a consequence of improved insulin sensitivity remains to be determined. Longitudinal studies of the effects of TZDs on  $\beta$ -cell function in human subjects are under way.

## MISCELLANEOUS PEPTIDE GROWTH FACTORS

Several peptides and growth factors promote expansion of  $\beta$ -cell mass in preclinical studies via effects on  $\beta$ -cell proliferation and/or apoptosis, or via stimulation of ductal proliferation and neogenesis (Table 1). Agents that act primarily on islet cells include insulin-like growth factor-1 (126), hepatocyte growth factor (127, 128), human placental lactogen (129), and parathyroid hormone-related peptide (130).

Treatment of rodents with keratinocyte growth factor induces pancreatic ductular proliferation and increases the number of functional insulin-secreting cells

following transplantation of human fetal islet preparations into rats (131). Administration of synthetic peptide fragments derived from islet-neogenesis-associated peptide (INGAP) promoted islet neogenesis in short-term studies of normal hamsters, and treatment of diabetic rodents with a pentadecapeptide derived from INGAP increased  $\beta$ -cell mass and improved glucose homeostasis in several preclinical studies (132). The molecular mechanisms activated by INGAP that result in expansion of  $\beta$ -cell mass remain incompletely understood.

## CONCLUSIONS

Progressive reductions in  $\beta$ -cell mass contribute significantly to the pathogenesis of type 2 diabetes. A major goal of diabetes research is to restore the  $\beta$ -cell mass typically lost during the natural progression of type 2 diabetes. The ability of GLP-1R agonists, and related peptides such as GIP, to enhance  $\beta$ -cell survival and stimulate  $\beta$ -cell growth in preclinical studies of diabetic animal models suggests that these agents could provide a noninvasive means to preserve and/or restore functional  $\beta$ -cell mass in patients with type 2 diabetes. Moreover, if these drugs are used early in the course of the disease, they could potentially delay or even prevent the progression to overt type 2 diabetes. However, whether these agents will produce a sustained improvement in  $\beta$ -cell function following chronic therapy in human patients with type 2 diabetes is currently not known. Long-term clinical studies will be required to answer this question.

## DISCLOSURE STATEMENT

LB is a consultant to Merck, Amylin, and Novonordisk. DJD is a consultant to Amylin, Lilly, Conjuchem, Merck, Novartis, Transition Therapeutics, Triad, Bristol Myers Squibb, GSK, and Johnson & Johnson.

## ACKNOWLEDGMENTS

Research in the Drucker laboratory related to studies of islet regeneration is supported in part by operating grants from the Juvenile Diabetes Research Foundation and the Canadian Diabetes Association. DJD is supported by a Canada Research Chair in Regulatory Peptides.

**The *Annual Review of Medicine* is online at <http://med.annualreviews.org>**

## LITERATURE CITED

1. Zimmet PZ. 1999. Diabetes epidemiology as a tool to trigger diabetes research and care. *Diabetologia* 42:499–518
2. Wild S, Roglic G, Green A, et al. 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 27:1047–53
3. Fagot-Campagna A, Narayan KMV, Imperatore G. 2001. Type 2 diabetes in children. *BMJ* 322:377–78

4. UK Prospective Diabetes Study (UKPDS) G. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 352:837–53
5. Butler AE, Janson J, Bonner-Weir S, et al. 2003. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes* 52:102–10
6. Kloppel G, Lohr M, Habich K, et al. 1985. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. *Surv. Synth. Pathol. Res.* 4:110–25
7. Sakuraba H, Mizukami H, Yagihashi N, et al. 2002. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. *Diabetologia* 45:85–96
8. Yoon KH, Ko SH, Cho JH, et al. 2003. Selective  $\beta$ -cell loss and  $\alpha$ -cell expansion in patients with type 2 diabetes mellitus in Korea. *J. Clin. Endocrinol. Metab.* 88:2300–8
9. Lingohr MK, Buettner R, Rhodes CJ. 2002. Pancreatic beta-cell growth and survival—a role in obesity-linked type 2 diabetes? *Trends Mol. Med.* 8:375–84
10. Bonner-Weir S. 2000. Life and death of the pancreatic beta cells. *Trends Endocrinol. Metab.* 11:375–78
11. Bonner-Weir S. 2000. Islet growth and development in the adult. *J. Mol. Endocrinol.* 24:297–302
12. Dickson LM, Rhodes CJ. 2004. Pancreatic beta-cell growth and survival in the onset of type 2 diabetes: a role for protein kinase B in the Akt? *Am. J. Physiol. Endocrinol. Metab.* 287: E192–98
13. Pick A, Clark J, Kubstrup C, et al. 1998. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. *Diabetes* 47:358–64
14. Portha B, Giroix MH, Serradas P, et al. 2001. Beta-cell function and viability in the spontaneously diabetic GK rat: information from the GK/Par colony. *Diabetes* 50 (Suppl. 1):S89–93
15. Donath MY, Halban PA. 2004. Decreased beta-cell mass in diabetes: significance, mechanisms and therapeutic implications. *Diabetologia* 47:581–89
16. Rhodes CJ. 2005. Type 2 diabetes—a matter of beta-cell life and death? *Science* 307:380–84
17. Efanova IB, Zaitsev SV, Zhivotovsky B, et al. 1998. Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular  $Ca^{2+}$  concentration. *J. Biol. Chem.* 273:33501–7
18. Maedler K, Carr RD, Bosco D, et al. 2005. Sulfonylurea induced beta-cell apoptosis in cultured human islets. *J. Clin. Endocrinol. Metab.* 90:501–6
19. Drucker DJ. 2002. Biological actions and therapeutic potential of the glucagon-like peptides. *Gastroenterology* 122:531–44
20. Baggio LL, Drucker DJ. 2004. Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2. *Best Pract. Res. Clin. Endocrinol. Metab.* 18:531–54
21. Prigeon RL, Quddusi S, Paty B, et al. 2003. Suppression of endogenous glucose production by glucagon-like peptide 1 independent of islet hormones: an extrapancreatic effect of an incretin hormone. *Am. J. Physiol. Endocrinol. Metab.* 285:E701–7
22. D'Alessio DA, Prigeon RL, Ensinnck JW. 1995. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I. *Diabetes* 44:1433–37
23. Zander M, Madsbad S, Madsen JL, et al. 2002. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell

- function in type 2 diabetes: a parallel-group study. *Lancet* 359:824–30
24. Drucker DJ. 2003. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. *Mol. Endocrinol.* 17:161–71
  25. Kieffer TJ, McIntosh CH, Pederson RA. 1995. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. *Endocrinology* 136:3585–96
  26. Mentlein R. 1999. Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. *Regul. Pept.* 85:9–24
  27. Hansen L, Deacon CF, Orskov C, et al. 1999. Glucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. *Endocrinology* 140:5356–63
  28. Ruiz-Grande C, Alarcon C, Alcantara A, et al. 1993. Renal catabolism of truncated glucagon-like peptide 1. *Horm. Metab. Res.* 25:612–16
  29. Meier JJ, Nauck MA, Kranz D, et al. 2004. Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. *Diabetes* 53:654–62
  30. Goke R, Fehmann HC, Linn T, et al. 1993. Exendin-4 is a high potency agonist and truncated exendin-(9–39)-amide an antagonist at the glucagon-like peptide 1-(7–36)-amide receptor of insulin-secreting beta-cells. *J. Biol. Chem.* 268:19650–55
  31. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. 2000. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. *J. Med. Chem.* 43:1664–69
  32. Susini S, Roche E, Prentki M, et al. 1998. Glucose and glucocretin peptides synergize to induce c-fos, c-jun, junB, zif-268, and nur-77 gene expression in pancreatic beta(INS-1) cells. *FASEB J.* 12:1173–82
  33. Buteau J, Roduit R, Susini S, et al. 1999. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. *Diabetologia* 42:856–64
  34. Zhou J, Wang X, Pineyro MA, et al. 1999. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. *Diabetes* 48:2358–66
  35. Hui H, Wright C, Perfetti R. 2001. Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. *Diabetes* 50:785–96
  36. Elbrond B, Jakobsen G, Larsen S, et al. 2002. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. *Diabetes Care* 25:1398–404
  37. Hui H, Nourparvar A, Zhao X, et al. 2003. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. *Endocrinology* 144:1444–55
  38. Li Y, Hansotia T, Yusta B, et al. 2003. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. *J. Biol. Chem.* 278:471–78
  39. Buteau J, El-Assaad W, Rhodes CJ, et al. 2004. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. *Diabetologia* 47:806–15
  40. Bregenholt S, Moldrup A, Blume N,

- et al. 2005. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. *Biochem. Biophys. Res. Commun.* 330:577–84
41. Edvell A, Lindstrom P. 1999. Initiation of increased pancreatic islet growth in young normoglycemic mice (Umea +/-). *Endocrinology* 140:778–83
  42. Xu G, Stoffers DA, Habener JF, et al. 1999. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. *Diabetes* 48:2270–76
  43. Stoffers DA, Kieffer TJ, Hussain MA, et al. 2000. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. *Diabetes* 49:741–48
  44. Perfetti R, Zhou J, Doyle ME, et al. 2000. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. *Endocrinology* 141:4600–5
  45. Rolin B, Larsen MO, Gotfredsen CF, et al. 2002. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. *Am. J. Physiol. Endocrinol. Metab.* 283:E745–E52
  46. Kim JG, Baggio LL, Bridon DP, et al. 2003. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. *Diabetes* 52:751–59
  47. Farilla L, Hui H, Bertolotto C, et al. 2002. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. *Endocrinology* 143:4397–408
  48. Wang Q, Brubaker PL. 2002. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. *Diabetologia* 45:1263–73
  49. Stoffers DA, Desai BM, DeLeon DD, et al. 2003. Neonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded rat. *Diabetes* 52:734–40
  50. Turrel C, Bailbe D, Lacorne M, et al. 2002. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. *Diabetes* 51:1443–52
  51. Movassat J, Beattie GM, Lopez AD, et al. 2002. Exendin 4 up-regulates expression of PDX 1 and hastens differentiation and maturation of human fetal pancreatic cells. *J. Clin. Endocrinol. Metab.* 87:4775–81
  52. Zhou J, Pineyro MA, Wang X, et al. 2002. Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factors. *J. Cell. Physiol.* 192:304–14
  53. Farilla L, Bulotta A, Hirshberg B, et al. 2003. GLP-1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. *Endocrinology* 144:5149–58
  54. De Leon DD, Deng S, Madani R, et al. 2003. Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. *Diabetes* 52:365–71
  55. Holz GG, Chepurny OG. 2005. Diabetes outfoxed by GLP-1? *Sci. STKE* 268:pe2
  56. Drucker DJ. 2003. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. *Endocrinology* 144:5145–48
  57. Brubaker PL, Drucker DJ. 2004. Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. *Endocrinology* 145:2653–59


58. Kodama S, Toyonaga T, Kondo T, et al. 2005. Enhanced expression of PDX-1 and Ngn3 by exendin-4 during beta cell regeneration in STZ-treated mice. *Biochem. Biophys. Res. Commun.* 327:1170–78
59. Buteau J, Foisy S, Joly E, et al. 2003. Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. *Diabetes* 52:124–32
60. Wang Q, Li L, Xu E, et al. 2004. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. *Diabetologia* 47:478–87
61. Accili D. 2004. Lilly lecture 2003: the struggle for mastery in insulin action: from triumvirate to republic. *Diabetes* 53:1633–42
62. Li Y, Hansotia T, Yusta B, et al. 2003. Glucagon-like peptide-1 receptor signaling modulates B cell apoptosis. *J. Biol. Chem.* 278:471–78
63. Jhala US, Canettieri G, Screaton RA, et al. 2003. cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. *Genes Dev.* 17:1575–80
64. Rachman J, Barrow BA, Levy JC, et al. 1997. Near normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. *Diabetologia* 40:205–11
65. Todd JF, Wilding JP, Edwards CM, et al. 1997. Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. *Eur. J. Clin. Invest.* 27:533–36
66. Toft-Nielsen MB, Madsbad S, Holst JJ. 1999. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. *Diabetes Care* 22:1137–43
67. Egan JM, Meneilly GS, Elahi D. 2003. Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. *Am. J. Physiol. Endocrinol. Metab.* 284:E1072–E1079
68. Kolterman OG, Buse JB, Fineman MS, et al. 2003. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. *J. Clin. Endocrinol. Metab.* 88:3082–89
69. DeFronzo RA, Ratner RE, Han J, et al. 2005. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care* 28:1092–100
70. Kendall DM, Riddle MC, Rosenstock J, et al. 2005. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. *Diabetes Care* 28:1083–91
71. Buse JB, Henry RR, Han J, et al. 2004. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care* 27:2628–35
72. Wideman RD, Kieffer TJ. 2004. Glucose-dependent insulinotropic polypeptide as a regulator of beta cell function and fate. *Horm. Metab. Res.* 36:782–86
73. Ehses JA, Casilla VR, Doty T, et al. 2003. Glucose-dependent insulinotropic polypeptide (GIP) promotes  $\beta$ -(INS-1) cell survival via cyclic AMP-mediated caspase-3 inhibition and regulation of p38 MAP kinase. *Endocrinology* 144:4433–45
74. Ehses JA, Pelech SL, Pederson RA, et al. 2002. Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. *J. Biol. Chem.* 277:37088–97
75. Trumper A, Trumper K, Trusheim H, et al. 2001. Glucose-dependent insulinotropic polypeptide is a growth

- factor for B (INS-1) cells by pleiotropic signaling. *Mol. Endocrinol.* 15:1559–70
76. Trumper A, Trumper K, Horsch D. 2002. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. *J. Endocrinol.* 174:233–46
  77. Kim SJ, Winter K, Nian C, et al. 2005. GIP stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3-K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1 and downregulation of bax expression. *J. Biol. Chem.* 280:22297–307
  78. Nauck MA, Heimesaat MM, Orskov C, et al. 1993. Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. *J. Clin. Invest.* 91:301–7
  79. Meier JJ, Hucking K, Holst JJ, et al. 2001. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. *Diabetes* 50:2497–504
  80. Lynn FC, Thompson SA, Pospisilik JA, et al. 2003. A novel pathway for regulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta cells. *FASEB J.* 17:91–93
  81. Meneilly GS, Bryer-Ash M, Elahi D. 1993. The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide. *Diabetes Care* 16:110–14
  82. Deacon CF, Nauck MA, Meier J, et al. 2000. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. *J. Clin. Endocrinol. Metab.* 85:3575–81
  83. Deacon CF, Nauck MA, Toft-Nielsen M, et al. 1995. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. *Diabetes* 44:1126–31
  84. Mest HJ, Mentlein R. 2005. Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. *Diabetologia* 48:616–20
  85. Ahren B, Holst JJ, Martensson H, et al. 2000. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. *Eur. J. Pharmacol.* 404:239–45
  86. Pederson RA, White HA, Schlenzig D, et al. 1998. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. *Diabetes* 47:1253–58
  87. Deacon CF, Hughes TE, Holst JJ. 1998. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. *Diabetes* 47:764–69
  88. Balkan B, Kwasnik L, Miserendino R, et al. 1999. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7–36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. *Diabetologia* 42:1324–31
  89. Pauly RP, Demuth HU, Rosche F, et al. 1999. Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. *Metabolism* 48:385–89
  90. Deacon CF, Danielsen P, Klarskov L, et al. 2001. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic effects in anesthetized pigs. *Diabetes* 50:1588–97
  91. Deacon CF, Wamberg S, Bie P, et al. 2002. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced


- incretin secretion in dogs. *J. Endocrinol.* 172:355–62
92. Pospisilik JA, Stafford SG, Demuth HU, et al. 2002. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. *Diabetes* 51:943–50
93. Pospisilik JA, Stafford SG, Demuth HU, et al. 2002. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. *Diabetes* 51:2677–83
94. Marguet D, Baggio L, Kobayashi T, et al. 2000. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. *Proc. Natl. Acad. Sci. USA* 97:6874–79
95. Ahren B, Simonsson E, Larsson H, et al. 2002. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. *Diabetes Care* 25:869–75
96. Ahren B, Landin-Olsson M, Jansson PA, et al. 2004. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. *J. Clin. Endocrinol. Metab.* 89:2078–84
97. Ahren B, Gomis R, Standl E, et al. 2004. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. *Diabetes Care* 27:2874–80
98. Zhu L, Tamvakopoulos C, Xie D, et al. 2003. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1–38). *J. Biol. Chem.* 278:22418–23
99. Yada T, Sakurada M, Filipsson K, et al. 2000. Intraperitoneal PACAP administration decreases blood glucose in GK rats, and in normal and high fat diet mice. *Ann. NY Acad. Sci.* 921:259–63
100. Yamamoto K, Hashimoto H, Tomimoto S, et al. 2003. Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. *Diabetes* 52:1155–62
101. Ahren B, Hughes TE. 2005. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. *Endocrinology* 146:2055–59
102. Hansotia T, Baggio LL, Delmeire D, et al. 2004. Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. *Diabetes* 53:1326–35
103. Pospisilik JA, Martin J, Doty T, et al. 2003. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. *Diabetes* 52:741–50
104. Reimer MK, Holst JJ, Ahren B. 2002. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. *Eur. J. Endocrinol.* 146:717–27
105. Conarello SL, Li Z, Ronan J, et al. 2003. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. *Proc. Natl. Acad. Sci. USA* 100:6825–30
106. Ryberg B, Axelson J, Hakanson R, et al. 1990. Trophic effects of continuous infusion of [Leu15]-gastrin-17 in the rat. *Gastroenterology* 98:33–38
107. Brand SJ, Fuller PJ. 1988. Differential gastrin gene expression in rat gastrointestinal tract and pancreas during

- neonatal development. *J. Biol. Chem.* 263:5341–47
108. Rooman I, Lardon J, Flamez D, et al. 2001. Mitogenic effect of gastrin and expression of gastrin receptors in duct-like cells of rat pancreas. *Gastroenterology* 121:940–49
109. Rooman I, Lardon J, Bouwens L. 2002. Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. *Diabetes* 51:686–90
110. Cras-Meneur C, Elghazi L, Czernichow P, et al. 2001. Epidermal growth factor increases undifferentiated pancreatic embryonic cells in vitro: a balance between proliferation and differentiation. *Diabetes* 50:1571–79
111. Krakowski ML, Kritzik MR, Jones EM, et al. 1999. Transgenic expression of epidermal growth factor and keratinocyte growth factor in beta-cells results in substantial morphological changes. *J. Endocrinol.* 162:167–75
112. Wang TC, Bonner-Weir S, Oates PS, et al. 1993. Pancreatic gastrin stimulates islet differentiation of transforming growth factor alpha-induced ductular precursor cells. *J. Clin. Invest.* 92:1349–56
113. Brand SJ, Tagerud S, Lambert P, et al. 2002. Pharmacological treatment of chronic diabetes by stimulating pancreatic beta-cell regeneration with systemic co-administration of EGF and gastrin. *Pharmacol. Toxicol.* 91:414–20
114. Rooman I, Bouwens L. 2004. Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57B16/J mice treated with alloxan. *Diabetologia* 47:259–65
- 114a. Suarez-Pinzon WL, Yan Y, Power R, et al. 2005. Combination therapy with epidermal growth factor and gastrin increases  $\beta$ -cell mass and reverses hyperglycemia in diabetic NOD mice. *Diabetes* 54:2596–601
115. Suarez-Pinzon WL, Lakey JR, Brand SJ, et al. 2005. Combination therapy with epidermal growth factor and gastrin induces neogenesis of human islet  $\beta$ -cells from pancreatic duct cells and an increase in functional  $\beta$ -cell mass. *J. Clin. Endocrinol. Metab.* 90:3401–9
116. Shapiro AM, Lakey JR, Ryan EA, et al. 2000. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. *N. Engl. J. Med.* 343:230–38
117. Kuntz E, Pinget M, Damge P. 2004. Cholecystokinin octapeptide: a potential growth factor for pancreatic beta cells in diabetic rats. *J. Pancreas* 5:464–75
118. Fursinn C, Waldhausl W. 2002. Thiazolidinediones: metabolic actions in vitro. *Diabetologia* 45:1211–23
119. Saltiel AR, Olefsky JM. 1996. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. *Diabetes* 45:1661–69
120. Yki-Jarvinen H. 2004. Thiazolidinediones. *N. Engl. J. Med.* 351:1106–18
121. Ovalle F, Bell DS. 2002. Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. *Diabetes Obes. Metab.* 4:56–59
122. Finegood DT, McArthur MD, Kojwang D, et al. 2001. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. *Diabetes* 50:1021–29
123. Ishida H, Takizawa M, Ozawa S, et al. 2004. Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: possible protection of beta cells from oxidative stress. *Metabolism* 53:488–94
124. Kawasaki F, Matsuda M, Kanda Y, et al. 2005. Structural and functional analysis of pancreatic islets preserved by

- pioglitazone in db/db mice. *Am. J. Physiol. Endocrinol. Metab.* 288:E510–E518
125. Zeender E, Maedler K, Bosco D, et al. 2004. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. *J. Clin. Endocrinol. Metab.* 89:5059–66
126. George M, Ayuso E, Casellas A, et al. 2002. Beta cell expression of IGF-I leads to recovery from type 1 diabetes. *J. Clin. Invest.* 109:1153–63
127. Otonkoski T, Cirulli V, Beattie M, et al. 1996. A role for hepatocyte growth factor/scatter factor in fetal mesenchyme-induced pancreatic beta-cell growth. *Endocrinology* 137:3131–39
128. Dai C, Li Y, Yang J, et al. 2003. Hepatocyte growth factor preserves beta cell mass and mitigates hyperglycemia in streptozotocin-induced diabetic mice. *J. Biol. Chem.* 278:27080–87
129. Vasavada RC, Garcia-Ocana A, Zawalich WS, et al. 2000. Targeted expression of placental lactogen in the beta cells of transgenic mice results in beta cell proliferation, islet mass augmentation, and hypoglycemia. *J. Biol. Chem.* 275:15399–406
130. Porter SE, Sorenson RL, Dann P, et al. 1998. Progressive pancreatic islet hyperplasia in the islet-targeted, parathyroid hormone-related protein-overexpressing mouse. *Endocrinology* 139:3743–51
131. Movassat J, Beattie GM, Lopez AD, et al. 2003. Keratinocyte growth factor and beta-cell differentiation in human fetal pancreatic endocrine precursor cells. *Diabetologia* 46:822–29
132. Rosenberg L, Lipsett M, Yoon JW, et al. 2004. A pentadecapeptide fragment of islet neogenesis-associated protein increases beta-cell mass and reverses diabetes in C57BL/6J mice. *Ann. Surg.* 240:875–84



**Figure 1** Pancreatic targets for expansion of  $\beta$ -cell mass by agents in clinical trials for the treatment of type 2 diabetes. Some evidence suggests that gastrin/epidermal growth factor (EGF) may increase the number of functional  $\beta$ -cells via the process of transdifferentiation. Glucagon-like peptide-1 receptor (GLP1-R) agonists and dipeptidyl peptidase-IV (DPP-IV) inhibitors exert their effects directly on islet  $\beta$ -cells and possibly on the pancreatic ductal epithelium. GIP, glucose-dependent insulinotropic polypeptide; TZDs, thiazolidinediones.



**Figure 2** Signal transduction pathways coupling GLP-1 receptor activation to expansion of β-cell mass.